Phase-0/Microdosing Network description
The Phase-0/Microdosing Network is the organizer of the stakeholder meeting. It was created to share news and ideas relevant to the research and applications of these approaches and increase their impact in drug development. Members include clinicians, scientists, regulators, Pharma, Biotech, CROs, patient advocacy groups and other non-profit organizations with interest in the potential of these approaches to provide safer, faster, and cheaper, live human data for drug development decision-making. The network aims to use the collective inter-disciplinary knowledge and skills to establish a versatile and comprehensive appreciation of the potential of these approaches to address developmental needs. Specifically, the network considers AMS/PET/LC-MS/MS methodologies and the continuum of microdosing and other Phase-0 approaches are complementary, synergistic, and cost-effective investigational tools for first-in-human, including first-in-patient studies. The network welcomes and encourages discussion of the limitations of these approaches, as aims to clarify their role in current and future drug development and identify criteria for their effective application. The network was founded by Tal Burt, M.D., Graeme Young, Ph.D., and Le Vuong, Ph.D.
Board of Directors
Tal Burt, M.D.
President & CEO
Dr. Burt is a clinical research and drug development consultant. He received his medical degree at the University of Florence, Italy, and trained in psychiatry and clinical research at New York University, Harvard, and Columbia University. He is a board-certified psychiatrist with more than 20-year experience in all phases of clinical development and expertise in the early-phase, proof-of-concept (POC), and microdosing stages of clinical development. He has led clinical research programs of drugs and devices in academia and industry, leading him to appreciate the challenges of new treatment development, including the huge expenses, wastes, uncertainties and risks involved, and the considerable burden on public health and research ethics that ineffective translational and clinical research lead to. He worked with regulators (FDA, Japan PMDA, Singapore HAS, India DFA), industry, academic, and patient advocacy stakeholders to address these challenges and accelerate development of novel therapeutics. He has authored 45 peer-reviewed publications in clinical research and drug development including original drug development methodologies such as Intra-Target Microdosing (ITM), randomized-withdrawal designs, assessment of the impact of false-negatives on the productivity of treatment development, the first publications of Vagus Nerve Stimulation (VNS) in major depression, the first comprehensive review of Transcranial Magnetic Stimulation (TMS), and a textbook on Outcomes Measurement in Clinical Psychiatry.
Graeme Young, Ph.D.
Co-Founder and Vice-President
Dr. Graeme Young is a Ph.D. scientist in GlaxoSmithKline Research and Development Ltd., where he has been employed in departments of Drug Metabolism for over 30 years. Graeme recently gained his Ph.D. (by published works) from University of Lincoln, UK (2015-2016) in Novel Approaches to Drug Development by Applications of Accelerator Mass Spectrometry (AMS). He has acted as a "champion" of AMS for many years, with responsibility for bringing AMS in-house to GSK and applying it to projects from Phase 0 to Phase 3. Graeme has been lead author or contributing author to many groundbreaking papers published on the subject of AMS and its application to Drug Metabolism and Bioanalysis. He was Chair of the Global Bioanalysis Consortium team on AMS, bringing together leaders in the field to help establish harmonized approaches to clinical study support using this enabling technology. Graeme is a co-founder of the Phase-0/Microdosing Network, a nonprofit international organization of multidisciplinary stakeholders with interests in accelerating translational drug development.
Malcolm Rowland, Ph.D.
Dr. Rowland is a pioneer of Clinical Pharmacology including microdosing approaches. He is professor Emeritus, University of Manchester and Adjunct Professor, University of California San Francisco. He received his B.Pharm (1961), PhD (1965) and D.Sc (1982) from University of London. He was a faculty member, School of Pharmacy, University of California San Francisco (1967-75). He has honorary doctorate degrees from the Universities of Poitiers (France), Uppsala (Sweden), and Athens (Greece), and Honorary Membership, Royal College of Physicians. He was President, EUFEPS (European Federation for Pharmaceutical Sciences,1996-2000). Dr. Rowland was the recipient of the American Society of Clinical Pharmacology and Therapeutics (ASCPT) 2012 Sheiner-Beal Award in Pharmacometrics, The FIP 2011 Host Madsen Award, and the 1994 AAPS Research Achievement Award in Pharmacokinetics, Pharmacodynamics and Drug Metabolism of AAPS. Professor Rowland's research interests are in pharmacokinetics, particularly the development and application of physiologically-based models, the prediction of pharmacokinetic behavior in humans, and intestinal drug absorption. He is the author of over 300 scientific publications and is the co-author of the textbook - Clinical Pharmacokinetics: Concepts and Applications.
Yuichi Sugiyama, Ph.D.
Dr. Sugiyama has been the Head of Sugiyama Laboratory, RIKEN Innovation Ctr, RIKEN Research Cluster for Innovation, Yokohama, Japan since April 2012. He had been Professor, Dept of Molecular Pharmacokinetics at the Univ of Tokyo since 1991 until 2012. His work is internationally recognized by many awards, including the American Association of Pharmaceutical Scientists Distinguished Pharmaceutical Scientist Award in 2003, the International Pharmaceutical Federation (FIP) Hoest Madsen Medal in 2009, the Medal with Purple Ribbon, a Medal of Honor given by the Japanese Government in 2010, the BB Brodie Award from the American Society for Pharmacology and Experimental Therapeutics in 2012, the RT Williams Distinguished Scientific Achievement Award from the International Society for the Study of Xenobiotics (ISSX) in 2013 and Rawls-Palmer Progress in Medicine Award from American Society for Clinical Pharmacology and Therapeutics in 2014. Dr. Sugiyama was listed as #1 scientist in 2007 for the number of citations he received in the preceding 10 years in the field of pharmacology and toxicology. He served as the chairman of Board of Pharmaceutical Sciences in FIP (2000-2004). He was also the president of both ISSX and the Japanese Society for Xenobiotic Metabolism and Disposition (2006-2007). He also led the Japanese government project on microdosing. The NEDO (New Energy and Industrial Technology Development Organization) project entitled “Establishment of Evolutional Drug development with the Use of Microdosing Clinical Trial” was adopted (2008-2011). In this project, the quantitative prediction method on ADME using modeling and simulation was applied to human to validate this methodology. That is, based on the in vitro data on metabolism, transport and binding with animal and human tissues, the drug concentration-time profiles in the plasma and target tissues such as liver and brain was predicted, and the validity of the predictions was investigated by using clinical studies under its microdose and therapeutic dose conditions. PET probes have been developed for specific transporters; for example, the effects of changes in OATP1B1 and MRP2 activity on systemic and hepatic exposure of some compounds were simulated using a physiologically-based pharmacokinetic (PBPK) model incorporating blood, liver (clearance and pharmacological target organ), and peripheral organs. Additionally, the microdose studies using unlabeled compounds only at low doses not only allowed estimation of the pharmacokinetic profiles of candidate drugs before clinical trials but also clarified the major factors dominating their pharmacokinetics when cassette doses of probe substrates were used in presence and absence of probe inhibitors. Such microdose studies should allow a quantitative understanding of the effects of genetic polymorphisms and drug-drug interaction of transporters on the pharmacokinetics of drugs and should open new avenues to drug development.
Saskia N. de Wildt, M.D., Ph.D.
Dr. de Wildt is a pediatric intensivist and associate professor in pediatric clinical pharmacology at Erasmus MC Sophia Children’s Hosp and serves as the Director of PharmaKids, the Erasmus Expertise Ctr for Pediatric Therapeutics and the Medicines for Children Research Ctr-the Netherlands. She received her PhD from Erasmus Univ and trained as a clinical pharmacologist at the Hosp for Sick Children in Toronto. Current Dutch Research Council and European Union supported research focuses on developmental pharmacology, more specifically on drug metabolism, drug transport and with a special interest in sedative and analgesic drugs. Dr de Wildt published over 65 international peer-reviewed papers in the field of pediatric pharmacology/intensive care. As a primary investigator, Dr. de Wildt holds currently 3 million euros in research grants, of which >2 million euros from the Dutch Research Council, ZonMW and the EU.
Oliver Langer, Ph.D.
Dr. Langer is Associate Professor at the Medical University of Vienna in Austria (Department of Clinical Pharmacology) and a Senior Scientist at the AIT Austrian Institute of Technology GmbH. He has studied pharmacy at the University of Vienna (Austria) and has received his PhD degree from the Karolinska Institute in Sweden. In his research, he uses preclinical and clinical PET to address different questions related to drug disposition and pharmacodynamics. Dr. Langer is an expert in PET-microdosing and has led research projects in this area, especially concerning transporter-mediated drug-drug interactions. He is author of 121 articles in peer-reviewed scientific journals and has a Hirsch (h) index of 33.
Wouter H.J. Vaes, Ph.D.
Dr. Vaes heads the Dept of Human Biology within the Netherlands Organisation for Applied Scientific Research (TNO). He received his PhD at the Research Inst of Toxicology at Utrecht Univ. Thereafter, he started working at TNO where he has been leading the Nutrients and Biomarker Group for about ten years. Dr. Vaes has managed programs on content analysis, bioavailability, health effects, drug-nutrient interactions, bioanalysis and elemental speciation sponsored by the Dutch government, EU-funding, and industry. The activities and his laboratories were transferred in 2012 to TNO Triskelion, aTNO subsidiary. Since that time, Dr. Vaes has been involved in the development of new technologies to increase the innovative strengths of TNO. One of his activities involves the installation of a 1 MV accelerator mass spectrometer (AMS) to be applied in innovative clinical research programs with isotopic radiotracers. The AMS laboratory has been fully operational since 2012, and its major achievement has been the development of a completely automatized sample introduction system. TNO has been involved in a number of studies, including pediatric microdosing and microtracer studies. Recently, TNO succeeded in performing the very first microdosing study with a therapeutic protein.
Joseph A. DiMasi, Ph.D.
Dr. DiMasi is Director of Economic Analysis and Research Associate Professor at the Tufts Center for the Study of Drug Development, Tufts Medical School, Tufts University. The Center is an independent non-profit multidisciplinary research organization that is committed to the exploration of scientific, economic, legal, and public policy issues related to pharmaceutical and biotechnology research, development, and regulation throughout the world. Dr. DiMasi is an internationally recognized expert on the economics of the pharmaceutical industry. He has published in a wide variety of economic, medical, and scientific journals, and has presented his research at numerous professional and industry conferences. Dr. DiMasi testified before the U.S. Congress in hearings leading up to the FDA Modernization Act of 1997 and reauthorization of the Prescription Drug User Fee Act. Dr. DiMasi’s research interests include the R&D cost of new drug development, risks in new drug development, factors that affect the length of the development and regulatory approval processes, innovation incentives for biopharmaceutical R&D, and changes in the structure and performance of the pharmaceutical and biotechnology industries.